metformin has been researched along with Sepsis in 37 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Sepsis: Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study is the most comprehensive meta-analysis at present, which shows that preadmission metformin use may reduce mortality and not increase the levels of serum creatinine and lactic acid in adult patients with sepsis and DM." | 9.12 | Association of Preadmission Metformin Use and Prognosis in Patients With Sepsis and Diabetes Mellitus: A Systematic Review and Meta-Analysis. ( Ding, X; Duan, Y; Guo, Y; Li, Y; Zhao, H, 2021) |
| "This meta-analysis indicated an association between metformin use prior to admission and lower mortality in septic adult patients with diabetes mellitus." | 9.01 | Association of preadmission metformin use and mortality in patients with sepsis and diabetes mellitus: a systematic review and meta-analysis of cohort studies. ( Ding, X; Kan, Q; Li, L; Liang, H; Sun, T; Wang, L; Wang, T, 2019) |
| "In our data, preadmission metformin use is associated with a significantly larger decrease in lactate after admission with sepsis or septic shock and with reduced mortality in septic shock." | 8.31 | New potential for an old kid on the block: Impact of premorbid metformin use on lactate kinetics, kidney injury and mortality in sepsis and septic shock, an observational study. ( De Decker, K; De Neve, N; Tackaert, T; Van Moorter, N; Van Vlem, B, 2023) |
| "This study showed that some pathological changes occurring in the lungs of aged rats, such as hemorrhage, edema, and inflammation, improved after metformin treatment; the number of hepatocyte death increased in the AgCLP group, and decreased in the AgMET group." | 8.31 | Effect of metformin on sepsis-associated acute lung injury and gut microbiota in aged rats with sepsis. ( Duo, B; Liu, Y; Lu, Z; Niu, Y; Wan, Y; Wang, S; Zhu, R, 2023) |
| "We conducted a retrospective cohort study to compare 90-day mortality in diabetic patients with sepsis with and without exposure to metformin during hospitalization." | 8.12 | Association of Metformin Use During Hospitalization and Mortality in Critically Ill Adults With Type 2 Diabetes Mellitus and Sepsis. ( Angus, DC; Chang, CH; Del Rio-Pertuz, G; Gómez, H; Kellum, JA; Liu, Q; Manrique-Caballero, CL; Murugan, R; Priyanka, P; Wang, S; Zuckerbraun, BS, 2022) |
| "These findings highlight a novel pathogenic mechanism of sepsis-related cognitive impairment through activation of inflammatory factors, and these are blocked by metformin to attenuate sepsis-induced neuronal injury and cognitive impairment." | 8.02 | Metformin attenuates sepsis-induced neuronal injury and cognitive impairment. ( Guo, C; Qin, Z; Xiao, X; Zhou, C, 2021) |
| "Our findings suggest that in CLP induced sepsis model, metformin can improve the function of blood and cardiac cells through alleviating inflammation, improvement of anti-inflammation properties, and enhancement of blood profile, and all these effects are more pronounced after 24 h in comparison with 12 h after induction of sepsis." | 8.02 | Short-term Effects of Metformin on Cardiac and Peripheral Blood Cells Following Cecal Ligation and Puncture-induced Sepsis. ( Abdollahi, M; Baeeri, M; Didari, T; Gholami, M; Haghi-Aminjan, H; Hassan, FI; Hassani, S; Mojtahedzadeh, M; Navaei-Nigjeh, M; Nejad, SM; Rahimifard, M, 2021) |
| "Prior metformin therapy was not significantly associated with the risk of sepsis and 30-day mortality after diagnosis of sepsis among diabetes patients." | 7.96 | Association between prior metformin therapy and sepsis in diabetes patients: a nationwide sample cohort study. ( Oh, TK; Song, IA, 2020) |
| "Background Metformin associated lactic acidosis (MALA) is a serious adverse event with a high mortality rate of 30-50%." | 7.96 | Identifying patients with metformin associated lactic acidosis in the emergency department. ( de Meijer, A; Gedik, A; Jansman, FGA; Taxis, K; van 't Riet, E; van Berlo-van de Laar, IRF, 2020) |
| "Lactate levels in metformin users were initially elevated in the early phase of resuscitation from severe sepsis and septic shock." | 7.85 | Impact of Metformin Use on Lactate Kinetics in Patients with Severe Sepsis and Septic Shock. ( Carriere, KC; Cha, WC; Hwang, SY; Jeon, K; Jo, IJ; Lee, TR; Park, J; Shin, TG; Sim, MS; Suh, GY; Yeon, S; Yoon, H, 2017) |
| "In 56 cases of severe metformin-associated lactic acidosis, blood pH and lactate did not have prognostic value." | 7.79 | The prognostic value of blood pH and lactate and metformin concentrations in severe metformin-associated lactic acidosis. ( Kajbaf, F; Lalau, JD, 2013) |
| "In this study of adult ED patients with suspected sepsis, metformin users had slightly higher median lactate levels and prevalence of hyperlactatemia." | 7.78 | Impact of metformin use on the prognostic value of lactate in sepsis. ( Berger, T; Garg, N; Green, JP; Hagar, Y; Panacek, EA; Radeos, MS; Suarez, A, 2012) |
| "To evaluate the significance of diabetes mellitus and metformin in patients admitted to medical ICU with lactic acidosis." | 7.78 | Lactic acidosis in medical ICU - the role of diabetes mellitus and metformin. ( Charvat, J; Havlin, J; Hloch, O; Masopust, J, 2012) |
| "Metformin, even at a dose mimicking accumulation, does not aggravate the mortality rate in this model of sepsis." | 7.73 | Effect of metformin on survival rate in experimental sepsis. ( Bouffandeau, B; Gras, V; Lalau, JD; Montravers, PH, 2006) |
| "Background: Sepsis is a life-threatening medical emergency, frequently complicated with intensive care unit-acquired weakness syndrome (ICU-AW)." | 5.91 | CELLULAR SENESCENCE IMPLICATED IN SEPSIS-INDUCED MUSCLE WEAKNESS AND AMELIORATED WITH METFORMIN. ( Chen, J; Chen, XY; Cong, XX; Huang, M; Sun, YT; Wang, S; Xu, SB; Zheng, LL; Zhou, YT, 2023) |
| "Metformin was administered at a dose of 100 mg/kg for a week before LPS intraperitoneal injection." | 5.91 | Metformin Alleviates Sepsis-Associated Myocardial Injury by Enhancing AMP-Activated Protein Kinase/Mammalian Target of Rapamycin Signaling Pathway-Mediated Autophagy. ( Cao, J; Chen, M; Gao, Y; Li, K; Li, R; Li, T; Liu, J; Shi, R; Wang, Y; Zhang, W; Zhang, X, 2023) |
| "GVHD had little effect." | 5.35 | O-glycoside biomarker of apolipoprotein C3: responsiveness to obesity, bariatric surgery, and therapy with metformin, to chronic or severe liver disease and to mortality in severe sepsis and graft vs host disease. ( Bernard, GR; Ely, EW; Harvey, SB; Homoncik, M; Jilma, B; Kasthuri, RS; Kellogg, TA; Lund, TC; Monkkonen, T; Nelsestuen, GL; Swan, T; Verneris, MR; Wilson-Grady, J; Zeisler, H; Zhang, Y, 2009) |
| "This study is the most comprehensive meta-analysis at present, which shows that preadmission metformin use may reduce mortality and not increase the levels of serum creatinine and lactic acid in adult patients with sepsis and DM." | 5.12 | Association of Preadmission Metformin Use and Prognosis in Patients With Sepsis and Diabetes Mellitus: A Systematic Review and Meta-Analysis. ( Ding, X; Duan, Y; Guo, Y; Li, Y; Zhao, H, 2021) |
| "This meta-analysis indicated an association between metformin use prior to admission and lower mortality in septic adult patients with diabetes mellitus." | 5.01 | Association of preadmission metformin use and mortality in patients with sepsis and diabetes mellitus: a systematic review and meta-analysis of cohort studies. ( Ding, X; Kan, Q; Li, L; Liang, H; Sun, T; Wang, L; Wang, T, 2019) |
| "In our data, preadmission metformin use is associated with a significantly larger decrease in lactate after admission with sepsis or septic shock and with reduced mortality in septic shock." | 4.31 | New potential for an old kid on the block: Impact of premorbid metformin use on lactate kinetics, kidney injury and mortality in sepsis and septic shock, an observational study. ( De Decker, K; De Neve, N; Tackaert, T; Van Moorter, N; Van Vlem, B, 2023) |
| "This study showed that some pathological changes occurring in the lungs of aged rats, such as hemorrhage, edema, and inflammation, improved after metformin treatment; the number of hepatocyte death increased in the AgCLP group, and decreased in the AgMET group." | 4.31 | Effect of metformin on sepsis-associated acute lung injury and gut microbiota in aged rats with sepsis. ( Duo, B; Liu, Y; Lu, Z; Niu, Y; Wan, Y; Wang, S; Zhu, R, 2023) |
| "We conducted a retrospective cohort study to compare 90-day mortality in diabetic patients with sepsis with and without exposure to metformin during hospitalization." | 4.12 | Association of Metformin Use During Hospitalization and Mortality in Critically Ill Adults With Type 2 Diabetes Mellitus and Sepsis. ( Angus, DC; Chang, CH; Del Rio-Pertuz, G; Gómez, H; Kellum, JA; Liu, Q; Manrique-Caballero, CL; Murugan, R; Priyanka, P; Wang, S; Zuckerbraun, BS, 2022) |
| "These findings highlight a novel pathogenic mechanism of sepsis-related cognitive impairment through activation of inflammatory factors, and these are blocked by metformin to attenuate sepsis-induced neuronal injury and cognitive impairment." | 4.02 | Metformin attenuates sepsis-induced neuronal injury and cognitive impairment. ( Guo, C; Qin, Z; Xiao, X; Zhou, C, 2021) |
| "Our findings suggest that in CLP induced sepsis model, metformin can improve the function of blood and cardiac cells through alleviating inflammation, improvement of anti-inflammation properties, and enhancement of blood profile, and all these effects are more pronounced after 24 h in comparison with 12 h after induction of sepsis." | 4.02 | Short-term Effects of Metformin on Cardiac and Peripheral Blood Cells Following Cecal Ligation and Puncture-induced Sepsis. ( Abdollahi, M; Baeeri, M; Didari, T; Gholami, M; Haghi-Aminjan, H; Hassan, FI; Hassani, S; Mojtahedzadeh, M; Navaei-Nigjeh, M; Nejad, SM; Rahimifard, M, 2021) |
| "Background Metformin associated lactic acidosis (MALA) is a serious adverse event with a high mortality rate of 30-50%." | 3.96 | Identifying patients with metformin associated lactic acidosis in the emergency department. ( de Meijer, A; Gedik, A; Jansman, FGA; Taxis, K; van 't Riet, E; van Berlo-van de Laar, IRF, 2020) |
| "Prior metformin therapy was not significantly associated with the risk of sepsis and 30-day mortality after diagnosis of sepsis among diabetes patients." | 3.96 | Association between prior metformin therapy and sepsis in diabetes patients: a nationwide sample cohort study. ( Oh, TK; Song, IA, 2020) |
| "Lactate levels in metformin users were initially elevated in the early phase of resuscitation from severe sepsis and septic shock." | 3.85 | Impact of Metformin Use on Lactate Kinetics in Patients with Severe Sepsis and Septic Shock. ( Carriere, KC; Cha, WC; Hwang, SY; Jeon, K; Jo, IJ; Lee, TR; Park, J; Shin, TG; Sim, MS; Suh, GY; Yeon, S; Yoon, H, 2017) |
| "Neither diabetes mellitus nor preadmission insulin or metformin use are associated with altered disease presentation, outcome or host response in patients with sepsis requiring intensive care." | 3.83 | Association of diabetes and diabetes treatment with the host response in critically ill sepsis patients. ( Bonten, MM; Cremer, OL; Hoogendijk, AJ; Horn, J; Klein Klouwenberg, PM; Nürnberg, P; Schultz, MJ; Scicluna, BP; van der Poll, T; van Vught, LA; Wiewel, MA, 2016) |
| "In 56 cases of severe metformin-associated lactic acidosis, blood pH and lactate did not have prognostic value." | 3.79 | The prognostic value of blood pH and lactate and metformin concentrations in severe metformin-associated lactic acidosis. ( Kajbaf, F; Lalau, JD, 2013) |
| "In this study of adult ED patients with suspected sepsis, metformin users had slightly higher median lactate levels and prevalence of hyperlactatemia." | 3.78 | Impact of metformin use on the prognostic value of lactate in sepsis. ( Berger, T; Garg, N; Green, JP; Hagar, Y; Panacek, EA; Radeos, MS; Suarez, A, 2012) |
| "To evaluate the significance of diabetes mellitus and metformin in patients admitted to medical ICU with lactic acidosis." | 3.78 | Lactic acidosis in medical ICU - the role of diabetes mellitus and metformin. ( Charvat, J; Havlin, J; Hloch, O; Masopust, J, 2012) |
| "We report a case of severe metabolic acidosis associated with acute renal failure and septicaemia following treatment with maximal therapeutic doses of metformin and diclofenac." | 3.73 | Intensive care treatment of severe mixed metabolic acidosis. ( Akeson, J; Christensson, A; Schmidt, A, 2005) |
| "Metformin, even at a dose mimicking accumulation, does not aggravate the mortality rate in this model of sepsis." | 3.73 | Effect of metformin on survival rate in experimental sepsis. ( Bouffandeau, B; Gras, V; Lalau, JD; Montravers, PH, 2006) |
| "Diabetes and sepsis are important causes of morbidity and mortality worldwide, and diabetic patients represent the largest population experiencing post-sepsis complications and rising mortality." | 2.72 | Type 2 diabetes mellitus and sepsis: state of the art, certainties and missing evidence. ( Brizzi, MF; Carlin, M; Costantini, E; Porta, M, 2021) |
| "Background: Sepsis is a life-threatening medical emergency, frequently complicated with intensive care unit-acquired weakness syndrome (ICU-AW)." | 1.91 | CELLULAR SENESCENCE IMPLICATED IN SEPSIS-INDUCED MUSCLE WEAKNESS AND AMELIORATED WITH METFORMIN. ( Chen, J; Chen, XY; Cong, XX; Huang, M; Sun, YT; Wang, S; Xu, SB; Zheng, LL; Zhou, YT, 2023) |
| "Metformin was administered at a dose of 100 mg/kg for a week before LPS intraperitoneal injection." | 1.91 | Metformin Alleviates Sepsis-Associated Myocardial Injury by Enhancing AMP-Activated Protein Kinase/Mammalian Target of Rapamycin Signaling Pathway-Mediated Autophagy. ( Cao, J; Chen, M; Gao, Y; Li, K; Li, R; Li, T; Liu, J; Shi, R; Wang, Y; Zhang, W; Zhang, X, 2023) |
| "GVHD had little effect." | 1.35 | O-glycoside biomarker of apolipoprotein C3: responsiveness to obesity, bariatric surgery, and therapy with metformin, to chronic or severe liver disease and to mortality in severe sepsis and graft vs host disease. ( Bernard, GR; Ely, EW; Harvey, SB; Homoncik, M; Jilma, B; Kasthuri, RS; Kellogg, TA; Lund, TC; Monkkonen, T; Nelsestuen, GL; Swan, T; Verneris, MR; Wilson-Grady, J; Zeisler, H; Zhang, Y, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (8.11) | 29.6817 |
| 2010's | 11 (29.73) | 24.3611 |
| 2020's | 23 (62.16) | 2.80 |
| Authors | Studies |
|---|---|
| Qin, Z | 1 |
| Zhou, C | 1 |
| Xiao, X | 1 |
| Guo, C | 1 |
| Li, Y | 1 |
| Zhao, H | 2 |
| Guo, Y | 2 |
| Duan, Y | 1 |
| Ding, X | 7 |
| Gómez, H | 1 |
| Del Rio-Pertuz, G | 1 |
| Priyanka, P | 1 |
| Manrique-Caballero, CL | 1 |
| Chang, CH | 1 |
| Wang, S | 3 |
| Liu, Q | 1 |
| Zuckerbraun, BS | 1 |
| Murugan, R | 1 |
| Angus, DC | 1 |
| Kellum, JA | 1 |
| Song, H | 3 |
| Zhang, X | 4 |
| Zhai, R | 2 |
| Liang, H | 6 |
| Song, G | 3 |
| Yuan, Y | 1 |
| Xu, Y | 1 |
| Yan, Y | 1 |
| Qiu, L | 1 |
| Sun, T | 6 |
| Wang, Y | 2 |
| Duan, X | 1 |
| Li, L | 2 |
| Kan, Q | 2 |
| Dardano, A | 1 |
| Aragona, M | 1 |
| Daniele, G | 1 |
| Miccoli, R | 1 |
| Del Prato, S | 1 |
| Wang, D | 1 |
| Lyu, Y | 1 |
| Sun, G | 1 |
| Vezza, T | 1 |
| Víctor, VM | 1 |
| Van Moorter, N | 3 |
| Tackaert, T | 3 |
| De Decker, K | 3 |
| Van Vlem, B | 3 |
| De Neve, N | 3 |
| Montoya, C | 1 |
| Chen, J | 1 |
| Chen, XY | 1 |
| Cong, XX | 1 |
| Xu, SB | 1 |
| Sun, YT | 1 |
| Zhou, YT | 1 |
| Zheng, LL | 1 |
| Huang, M | 1 |
| Wan, Y | 1 |
| Niu, Y | 1 |
| Duo, B | 1 |
| Liu, Y | 1 |
| Lu, Z | 1 |
| Zhu, R | 1 |
| Gao, Y | 1 |
| Liu, J | 1 |
| Li, K | 1 |
| Li, T | 1 |
| Li, R | 1 |
| Zhang, W | 1 |
| Chen, M | 1 |
| Shi, R | 1 |
| Cao, J | 1 |
| Oh, TK | 1 |
| Song, IA | 1 |
| Honore, PM | 1 |
| Mugisha, A | 1 |
| Kugener, L | 1 |
| Redant, S | 1 |
| Attou, R | 1 |
| Gallerani, A | 1 |
| De Bels, D | 1 |
| van Berlo-van de Laar, IRF | 1 |
| Gedik, A | 1 |
| van 't Riet, E | 1 |
| de Meijer, A | 1 |
| Taxis, K | 1 |
| Jansman, FGA | 1 |
| Didari, T | 1 |
| Hassani, S | 1 |
| Baeeri, M | 1 |
| Navaei-Nigjeh, M | 1 |
| Rahimifard, M | 1 |
| Haghi-Aminjan, H | 1 |
| Gholami, M | 1 |
| Nejad, SM | 1 |
| Hassan, FI | 1 |
| Mojtahedzadeh, M | 1 |
| Abdollahi, M | 1 |
| Knuth, CM | 1 |
| Auger, C | 1 |
| Jeschke, MG | 1 |
| Costantini, E | 1 |
| Carlin, M | 1 |
| Porta, M | 1 |
| Brizzi, MF | 1 |
| Asgharzadeh, F | 1 |
| Barneh, F | 1 |
| Fakhraie, M | 1 |
| Adel Barkhordar, SL | 1 |
| Shabani, M | 1 |
| Soleimani, A | 1 |
| Rahmani, F | 1 |
| Ariakia, F | 1 |
| Mehraban, S | 1 |
| Avan, A | 1 |
| Hashemzehi, M | 1 |
| Arjmand, MH | 1 |
| Behnam-Rassouli, R | 1 |
| Jaberi, N | 1 |
| Sayyed-Hosseinian, SH | 1 |
| Ferns, GA | 1 |
| Ryzhikov, M | 1 |
| Jafari, M | 1 |
| Khazaei, M | 1 |
| Hassanian, SM | 1 |
| Trovato, FM | 1 |
| Martines, GF | 1 |
| Noto, P | 1 |
| Mangano, G | 1 |
| Malatino, L | 1 |
| Carpinteri, G | 1 |
| Muharremi, S | 1 |
| Wang, T | 1 |
| Wang, L | 1 |
| Ye, J | 1 |
| Liang, Q | 1 |
| Xi, X | 1 |
| Kajbaf, F | 1 |
| Lalau, JD | 2 |
| Vaez, H | 1 |
| Rameshrad, M | 1 |
| Najafi, M | 1 |
| Barar, J | 1 |
| Barzegari, A | 1 |
| Garjani, A | 1 |
| van Vught, LA | 1 |
| Scicluna, BP | 1 |
| Hoogendijk, AJ | 1 |
| Wiewel, MA | 1 |
| Klein Klouwenberg, PM | 1 |
| Cremer, OL | 1 |
| Horn, J | 1 |
| Nürnberg, P | 1 |
| Bonten, MM | 1 |
| Schultz, MJ | 1 |
| van der Poll, T | 1 |
| Park, J | 1 |
| Hwang, SY | 1 |
| Jo, IJ | 1 |
| Jeon, K | 1 |
| Suh, GY | 1 |
| Lee, TR | 1 |
| Yoon, H | 1 |
| Cha, WC | 1 |
| Sim, MS | 1 |
| Carriere, KC | 1 |
| Yeon, S | 1 |
| Shin, TG | 1 |
| van den Nouland, DP | 1 |
| Brouwers, MC | 1 |
| Stassen, PM | 1 |
| Harvey, SB | 1 |
| Zhang, Y | 1 |
| Wilson-Grady, J | 1 |
| Monkkonen, T | 1 |
| Nelsestuen, GL | 1 |
| Kasthuri, RS | 1 |
| Verneris, MR | 1 |
| Lund, TC | 1 |
| Ely, EW | 1 |
| Bernard, GR | 1 |
| Zeisler, H | 1 |
| Homoncik, M | 1 |
| Jilma, B | 1 |
| Swan, T | 1 |
| Kellogg, TA | 1 |
| Green, JP | 1 |
| Berger, T | 1 |
| Garg, N | 1 |
| Suarez, A | 1 |
| Hagar, Y | 1 |
| Radeos, MS | 1 |
| Panacek, EA | 1 |
| Hloch, O | 1 |
| Charvat, J | 1 |
| Masopust, J | 1 |
| Havlin, J | 1 |
| Schmidt, A | 1 |
| Christensson, A | 1 |
| Akeson, J | 1 |
| Gras, V | 1 |
| Bouffandeau, B | 1 |
| Montravers, PH | 1 |
4 reviews available for metformin and Sepsis
| Article | Year |
|---|---|
Association of Preadmission Metformin Use and Prognosis in Patients With Sepsis and Diabetes Mellitus: A Systematic Review and Meta-Analysis.
Topics: Diabetes Mellitus, Type 2; Diagnostic Tests, Routine; Humans; Hypoglycemic Agents; Metformin; Mortal | 2021 |
Burn-induced hypermetabolism and skeletal muscle dysfunction.
Topics: Burns; Cachexia; Epigenesis, Genetic; Exercise; Human Growth Hormone; Humans; Insulin; Metformin; Mu | 2021 |
Type 2 diabetes mellitus and sepsis: state of the art, certainties and missing evidence.
Topics: Acute Kidney Injury; Diabetes Mellitus, Type 2; Humans; Insulin; Metformin; Sepsis | 2021 |
Association of preadmission metformin use and mortality in patients with sepsis and diabetes mellitus: a systematic review and meta-analysis of cohort studies.
Topics: Diabetes Mellitus; Hospital Mortality; Humans; Hypoglycemic Agents; Metformin; Observational Studies | 2019 |
33 other studies available for metformin and Sepsis
| Article | Year |
|---|---|
Metformin attenuates sepsis-induced neuronal injury and cognitive impairment.
Topics: Animals; Brain; Cecum; Cognition; Cognition Disorders; Cognitive Dysfunction; Disease Models, Animal | 2021 |
Association of Metformin Use During Hospitalization and Mortality in Critically Ill Adults With Type 2 Diabetes Mellitus and Sepsis.
Topics: Adult; Critical Illness; Diabetes Mellitus, Type 2; Hospitalization; Humans; Metformin; Retrospectiv | 2022 |
Metformin attenuated sepsis-associated liver injury and inflammatory response in aged mice.
Topics: Aging; Animals; Inflammation; Lipopolysaccharides; Liver; Liver Diseases; Male; Metformin; Mice; Mic | 2022 |
Metformin attenuated sepsis-related liver injury by modulating gut microbiota.
Topics: Animals; Gastrointestinal Microbiome; Liver; Metformin; Rats; RNA, Ribosomal, 16S; Sepsis | 2022 |
Efficacy of Dulaglutide in a Patient With Type 2 Diabetes, High Cardiovascular Risk, and HIV: A Case Report.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucagon-Like Peptide-1 Receptor; Glucag | 2022 |
Metformin Improves the Prognosis of Adult Mice with Sepsis-Associated Encephalopathy Better than That of Aged Mice.
Topics: Animals; Lipopolysaccharides; Metformin; Mice; Microglia; NF-kappa B; Prognosis; Sepsis; Sepsis-Asso | 2022 |
Metformin Mitigates Sepsis-Related Neuroinflammation
Topics: Animals; Gastrointestinal Microbiome; Humans; Metformin; Neuroinflammatory Diseases; Rats; RNA, Ribo | 2022 |
Metformin: An Intriguing Protective Agent in Hospitalized Diabetic Patients With Sepsis.
Topics: Diabetes Mellitus; Humans; Hypoglycemic Agents; Metformin; Protective Agents; Sepsis | 2022 |
New potential for an old kid on the block: Impact of premorbid metformin use on lactate kinetics, kidney injury and mortality in sepsis and septic shock, an observational study.
Topics: Acute Kidney Injury; Humans; Kidney; Lactic Acid; Metformin; Retrospective Studies; Sepsis; Shock, S | 2023 |
New potential for an old kid on the block: Impact of premorbid metformin use on lactate kinetics, kidney injury and mortality in sepsis and septic shock, an observational study.
Topics: Acute Kidney Injury; Humans; Kidney; Lactic Acid; Metformin; Retrospective Studies; Sepsis; Shock, S | 2023 |
New potential for an old kid on the block: Impact of premorbid metformin use on lactate kinetics, kidney injury and mortality in sepsis and septic shock, an observational study.
Topics: Acute Kidney Injury; Humans; Kidney; Lactic Acid; Metformin; Retrospective Studies; Sepsis; Shock, S | 2023 |
New potential for an old kid on the block: Impact of premorbid metformin use on lactate kinetics, kidney injury and mortality in sepsis and septic shock, an observational study.
Topics: Acute Kidney Injury; Humans; Kidney; Lactic Acid; Metformin; Retrospective Studies; Sepsis; Shock, S | 2023 |
Clarification of Key Points in a Study Evaluating the Association of Metformin and Mortality in Patients With Sepsis and Type 2 Diabetes.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Patients; Sepsis | 2023 |
CELLULAR SENESCENCE IMPLICATED IN SEPSIS-INDUCED MUSCLE WEAKNESS AND AMELIORATED WITH METFORMIN.
Topics: Animals; Cellular Senescence; Lipopolysaccharides; Metformin; Mice; Muscle Weakness; Sepsis; Tumor S | 2023 |
Effect of metformin on sepsis-associated acute lung injury and gut microbiota in aged rats with sepsis.
Topics: Acute Lung Injury; Animals; Escherichia coli; Gastrointestinal Microbiome; Inflammation; Interleukin | 2023 |
Metformin Alleviates Sepsis-Associated Myocardial Injury by Enhancing AMP-Activated Protein Kinase/Mammalian Target of Rapamycin Signaling Pathway-Mediated Autophagy.
Topics: AMP-Activated Protein Kinases; Animals; Autophagy; Lipopolysaccharides; Mammals; Metformin; Mice; Mi | 2023 |
Association between prior metformin therapy and sepsis in diabetes patients: a nationwide sample cohort study.
Topics: Adult; Cohort Studies; Diabetes Mellitus; Diabetes Mellitus, Type 2; Humans; Metformin; Propensity S | 2020 |
Association between metformin use prior to admission and lower mortality in septic adult patients with diabetes mellitus: beware of potential confounders.
Topics: Adult; Cohort Studies; Diabetes Mellitus; Humans; Hypoglycemic Agents; Metformin; Sepsis | 2020 |
Response to "Association between metformin use prior to admission and lower mortality in septic adult patients with diabetes mellitus: beware of potential confounders".
Topics: Adult; Cohort Studies; Diabetes Mellitus; Humans; Hypoglycemic Agents; Metformin; Sepsis | 2020 |
Identifying patients with metformin associated lactic acidosis in the emergency department.
Topics: Acidosis, Lactic; Aged; Aged, 80 and over; Creatinine; Emergency Service, Hospital; Female; Humans; | 2020 |
Short-term Effects of Metformin on Cardiac and Peripheral Blood Cells Following Cecal Ligation and Puncture-induced Sepsis.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Biomarkers; Blood Cells; Cecum; Disease Models, Ani | 2021 |
Metformin inhibits polyphosphate-induced hyper-permeability and inflammation.
Topics: AMP-Activated Protein Kinase Kinases; Animals; Anti-Inflammatory Agents; Capillary Permeability; Cel | 2021 |
Metformin-associated lactic acidosis: Are we looking in the right direction?
Topics: Acidosis, Lactic; Acute Kidney Injury; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metfo | 2020 |
FOURNIER'S GANGRENE, A RARE COMPLICATION OF DIABETES MELLITUS (CASE REPORT).
Topics: Diabetes Mellitus, Type 2; Fatal Outcome; Fournier Gangrene; Humans; Hypoglycemic Agents; Kidney Fai | 2018 |
Some questions about preadmission metformin use and mortality in patients with sepsis and diabetes mellitus.
Topics: Cohort Studies; Humans; Hypoglycemic Agents; Metformin; Sepsis | 2019 |
Response.
Topics: Diabetes Mellitus; Humans; Metformin; Sepsis | 2019 |
The prognostic value of blood pH and lactate and metformin concentrations in severe metformin-associated lactic acidosis.
Topics: Acidosis, Lactic; Adult; Aged; Aged, 80 and over; Drug Monitoring; Drug Overdose; Female; Humans; Hy | 2013 |
Cardioprotective effect of metformin in lipopolysaccharide-induced sepsis via suppression of toll-like receptor 4 (TLR4) in heart.
Topics: AMP-Activated Protein Kinases; Animals; Body Weight; Cardiotonic Agents; Gene Expression Regulation; | 2016 |
Association of diabetes and diabetes treatment with the host response in critically ill sepsis patients.
Topics: Aged; Biomarkers; Chemokine CX3CL1; Critical Illness; Diabetes Mellitus; E-Selectin; Female; Humans; | 2016 |
Impact of Metformin Use on Lactate Kinetics in Patients with Severe Sepsis and Septic Shock.
Topics: Aged; Emergency Service, Hospital; Female; Hospital Mortality; Humans; Lactic Acid; Male; Metformin; | 2017 |
Prognostic value of plasma lactate levels in a retrospective cohort presenting at a university hospital emergency department.
Topics: Aged; Aged, 80 and over; Comorbidity; Diabetes Mellitus; Emergency Service, Hospital; Female; Hospit | 2017 |
O-glycoside biomarker of apolipoprotein C3: responsiveness to obesity, bariatric surgery, and therapy with metformin, to chronic or severe liver disease and to mortality in severe sepsis and graft vs host disease.
Topics: Adult; Aged; Apolipoprotein C-III; Bariatric Surgery; Biomarkers; Diabetes Mellitus; Female; Glycosi | 2009 |
Impact of metformin use on the prognostic value of lactate in sepsis.
Topics: Aged; Emergency Service, Hospital; Female; Humans; Hypoglycemic Agents; Lactates; Logistic Models; M | 2012 |
Lactic acidosis in medical ICU - the role of diabetes mellitus and metformin.
Topics: Acidosis, Lactic; Acute Kidney Injury; Aged; Critical Care; Diabetes Mellitus, Type 2; Female; Hospi | 2012 |
Intensive care treatment of severe mixed metabolic acidosis.
Topics: Abdominal Abscess; Acidosis; Acute Kidney Injury; Aged; Anti-Inflammatory Agents, Non-Steroidal; Blo | 2005 |
Effect of metformin on survival rate in experimental sepsis.
Topics: Animals; Blood Glucose; Death; Disease Models, Animal; Injections, Intraperitoneal; Lethal Dose 50; | 2006 |